Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort

Among patients with HER2-positive metastatic breast cancer who experienced isolated CNS progression after receiving first-line trastuzumab and pertuzumab (T/P), continuing T/P after local treatment did not negatively impact PFS and OS, according to data from a retrospective review of real-life data. No difference in PFS was seen for patients who continued T/P or switched to another systemic treatment, and T/P continuation was associated with longer OS (HR 0.28; 95% CI: 0.14–0.54; p < 0.001).